

I hereby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office (Fax No.: 1-703-872-9306)

On February 21, 2002

TOWNSEND and TOWNSEND and CREW LLP

By: Rosemarie L. Celli
Rosemarie L. Celli

PATENT
Attorney Docket No.: 15270J-005910US
Client Ref. No.: 209-US-NEW6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Dale B. Schenk

Application No.: 09/585,817

Filed: June 1, 2000

For: PHARMACEUTICAL
COMPOSITIONS AND METHODS FOR
TREATMENT OF AMYLOID
DISEASES

Examiner: Fozia Hamud

Art Unit: 1647

**RESPONSE TO
RESTRICTION/ELECTION OF SPECIES
REQUIREMENT**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicant files this response to the Restriction/Election of Species Requirement mailed September 21, 2001. A petition for an extend the time of response to the Office mailed September 21, 2001 from October 21, 2001 to February 21, 2002 is transmitted hereto.

REMARKS

The paragraph numbering of the Restriction/Election of Species Requirement is used in responding to the Examiner's remarks.

1. Applicant elects Group II (claims 11-25).
2. Applicant traverses the Restriction Requirement, and provisionally elects prion precursor protein (PrP) of claim 13, and the ASer of claim 15. Applicant acknowledges the Examiner's comment that Applicant is required to elect a single amyloid component, i.e.